Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer
Authors
Keywords
-
Journal
Journal of Medical Imaging and Radiation Oncology
Volume 58, Issue 1, Pages 89-97
Publisher
Wiley
Online
2014-02-15
DOI
10.1111/1754-9485.12155
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions
- (2013) Jean-Mathieu Beauregard et al. NUCLEAR MEDICINE COMMUNICATIONS
- The prognostic significance of hypoxia inducing factor 1-α in oropharyngeal cancer in relation to human papillomavirus status
- (2012) Angela Hong et al. ORAL ONCOLOGY
- Development of a Hypoxia Gene Expression Classifier with Predictive Impact for Hypoxic Modification of Radiotherapy in Head and Neck Cancer
- (2011) K. Toustrup et al. CANCER RESEARCH
- More Lessons Learned From the Suffocation of Hypoxia
- (2010) K. Kian Ang JOURNAL OF CLINICAL ONCOLOGY
- p16 Expression As a Predictive Biomarker of Hypoxic Cell–Sensitizing Agents in Oropharyngeal Cancer
- (2010) Christine H. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance of p16INK4Aand Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial
- (2010) Danny Rischin et al. JOURNAL OF CLINICAL ONCOLOGY
- Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group
- (2010) Danny Rischin et al. JOURNAL OF CLINICAL ONCOLOGY
- Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
- (2010) Lester J. Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- HPV-associated head and neck cancer: a virus-related cancer epidemic
- (2010) Shanthi Marur et al. LANCET ONCOLOGY
- Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
- (2010) K. Kian Ang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients
- (2009) K. Settle et al. Cancer Prevention Research
- The Relationship Between Human Papillomavirus Status and Other Molecular Prognostic Markers in Head and Neck Squamous Cell Carcinomas
- (2009) Christina S. Kong et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Effect of HPV-Associated p16INK4A Expression on Response to Radiotherapy and Survival in Squamous Cell Carcinoma of the Head and Neck
- (2009) Pernille Lassen et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative Prognostic Value of HPV16 E6 mRNA Compared With In Situ Hybridization for Human Oropharyngeal Squamous Carcinoma
- (2009) Wei Shi et al. JOURNAL OF CLINICAL ONCOLOGY
- HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer
- (2009) Pernille Lassen et al. RADIOTHERAPY AND ONCOLOGY
- Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial
- (2008) C. Fakhry et al. JNCI-Journal of the National Cancer Institute
- Distinct Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–Negative Head and Neck Cancers
- (2008) Maura L. Gillison et al. JNCI-Journal of the National Cancer Institute
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started